Your browser doesn't support javascript.
loading
Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases.
Lee, Sung-Bau; Chang, Ting-Yu; Lee, Nian-Zhe; Yu, Zih-Yao; Liu, Chi-Yuan; Lee, Hsueh-Yun.
Afiliación
  • Lee SB; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Chang TY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Lee NZ; Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Yu ZY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Liu CY; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Lee HY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical Univer
Eur J Med Chem ; 227: 113904, 2022 Jan 05.
Article en En | MEDLINE | ID: mdl-34662748
This study presents the design, synthesis, and characterization of bisindole molecules as anti-cancer agents against Tousled-like kinases (TLKs). We show that compound 2 composed of an indirubin-3'-oxime group linked with a (N-methylpiperidin-2-yl)ethyl moiety possessed inhibitory activity toward both TLK1 and TLK2 in vitro and diminished the phosphorylation level of the downstream substrate anti-silencing function 1 (ASF1) in replicating cells. The treatment of compound 2 impaired DNA replication, slowed S-phase progression, and triggered DNA damage response in replicating cells. Structure optimization further discovered six derivatives exhibiting potent TLK inhibitory activity and revealed the importance of the tertiary amine-containing moiety of the side chain. Moreover, the derivatives 6, 17, 19, and 20 strongly suppressed the growth of triple-negative breast cancer MDA-MB-231 cells, non-small cell lung cancer A549 cells, and colorectal cancer HCT-116 cells, while normal lung fibroblast MRC5 and IMR90 cells showed a lower response to these compounds. Taken together, this study identifies tertiary amine-linked indirubin-3'-oximes as potent anticancer agents that inhibit TLK activity.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diseño de Fármacos / Proteínas Serina-Treonina Quinasas / Alcaloides Indólicos / Inhibidores de Proteínas Quinasas / Antineoplásicos Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diseño de Fármacos / Proteínas Serina-Treonina Quinasas / Alcaloides Indólicos / Inhibidores de Proteínas Quinasas / Antineoplásicos Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Francia